BioMarin to reduce global workforce by about 225 employees

Reuters Images

The decision comes in the wake of the company's updated strategy for its hemophilia gene therapy

Sriparna Roy, Reuters News

August 29, 2024

PHOTO

BioMarin Pharmaceutical will reduce its global workforce by about 225 employees, a filing showed on Wednesday.

The decision comes in the wake of the company's updated strategy for its hemophilia gene therapy, Roctavian, and the discontinuation of its gene therapy BMN 293 development program.

Earlier this month, BioMarin said it will refocus Roctavian's commercial operations on three key markets: the United States, Germany, and Italy

(Reporting by Sriparna Roy in Bengaluru; Editing by Maju Samuel and Tasim Zahid)

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.